Last reviewed · How we verify
Calcium Dobesilate Capsules
Calcium dobesilate reduces capillary fragility and improves microcirculation by decreasing blood viscosity and enhancing red blood cell deformability.
Calcium dobesilate reduces capillary fragility and improves microcirculation by decreasing blood viscosity and enhancing red blood cell deformability. Used for Diabetic retinopathy, Diabetic angiopathy, Venous insufficiency.
At a glance
| Generic name | Calcium Dobesilate Capsules |
|---|---|
| Also known as | Doxium，H20140641 |
| Sponsor | Affiliated Hospital of Nantong University |
| Drug class | Vascular protectant / Capillary stabilizer |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Vascular disorders |
| Phase | FDA-approved |
Mechanism of action
Calcium dobesilate is a vascular protectant that acts on the microvasculature by reducing capillary permeability and fragility. It improves blood flow through microvessels by decreasing blood viscosity and increasing erythrocyte deformability, thereby enhancing oxygen delivery to tissues. These properties make it useful in conditions characterized by microvascular dysfunction.
Approved indications
- Diabetic retinopathy
- Diabetic angiopathy
- Venous insufficiency
- Hemorrhoids
- Microvascular disorders
Common side effects
- Gastrointestinal disturbances
- Headache
- Dizziness
- Rash
Key clinical trials
- Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients (PHASE2)
- A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma (PHASE3)
- UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (PHASE3)
- Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery (PHASE4)
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
- Selinexor and Backbone Treatments of Multiple Myeloma Patients (PHASE1, PHASE2)
- Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM (PHASE1, PHASE2)
- ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcium Dobesilate Capsules CI brief — competitive landscape report
- Calcium Dobesilate Capsules updates RSS · CI watch RSS
- Affiliated Hospital of Nantong University portfolio CI